Advertisement

Antibiotic Treatment in Atherosclerosis and Myocardial Infarction

  • S. Gupta
  • J. C. Kaski

Abstract

Evidence is accumulating to suggest that Chlamydia pneumoniae may have a role in the development and/or progression of atherosclerotic-related disorders, in particular coronary heart disease (CHD). The evidence for C. pneumoniae as a potential causative agent is largely based on the findings of (1) seroepidemiological studies, (2) examination of atheromatous plaque specimens, (3) in vitro experiments and animal models and, recently, (4) preliminary anti-chlamydial antibiotic intervention studies. This chapter aims at focusing on the potential, and intriguing, role of antimicrobial therapy in the secondary prevention of CHD. The findings of the preliminary pilot studies are reviewed, as are the aims and controversies surrounding large-scale, prospective intervention trials, now in progress.

Keywords

Coronary Heart Disease Antibody Titre Chlamydial Infection Prevalent Coronary Heart Disease Coronary Endarterectomy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mendall MA, Carrington D, Strachan D et al (1995) Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease. J Infect 30: 121–128PubMedCrossRefGoogle Scholar
  2. 2.
    Saikku P, Mattila K, Nieminen MS et al (1988) Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 2: 983–986PubMedCrossRefGoogle Scholar
  3. 3.
    Thom DH, Grayston JT, Siscovick DS et al (1992) Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA 268: 68–72PubMedCrossRefGoogle Scholar
  4. 4.
    Patel P, Mendall MA, Carrington D et al (1995) Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 311: 711–714PubMedCrossRefGoogle Scholar
  5. 5.
    Leatham EWL, Bath PM, Tooze JA et al (1995) Increased monocyte tissue factor expression in coronary disease. Br Heart J 73: 10–13PubMedCrossRefGoogle Scholar
  6. 6.
    Gupta S, Leatham EW, Carrington D et al (1997) The effect of azithromycin in post myocardial infarction patients with elevated Chlamydia pneumoniae antibody titres. J Am Coll Cardiol 755: 209 (abstract)Google Scholar
  7. 7.
    Gupta S, Leatham EW, Carrington D et al (1997) Elevated Chlamydia penumoniae antibodies, cardiovascular events and azithromycin in male survivors of myocardial infarction. Circulation 96: 404–407PubMedGoogle Scholar
  8. 8.
    Rizzato G, Montemurro L, Fraioli P et al (1995) Efficacy of a three day course of azithromycin in moderately severe community-acquired pnumonia. Eur Respir J 8: 398–402PubMedCrossRefGoogle Scholar
  9. 9.
    Foulds G, Shepard RM, Johnson RB et al (1990) The pharmacokinetic of azithromycin in human serum and tissue. J Antimicrob Chemother 25[Suppl A]: 73–82PubMedGoogle Scholar
  10. 10.
    Black PN (1997) Anti-inflammatory effects of macrolide antibiotics. Eur Respir J 10: 971–972PubMedCrossRefGoogle Scholar
  11. 11.
    Gurfinkel E, Bozovich G, Daroca A et al (1997) Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 350: 404–407PubMedCrossRefGoogle Scholar
  12. 12.
    Sinisalo J, Mattila K, Nieminen MS et al (1998) The effect of prolonged doxycycline therapy on Chlamydia pneumoniae serological markers, coronary heart disease risk factor and forearm basal nitric oxide production. J Antimicrob Chemother 41: 85–92PubMedCrossRefGoogle Scholar
  13. 13.
    Anderson JL, Muhlestein JB (1998) Azithromycin in coronary artery disease: elimination of myocardial infection with Chlamydia. ACADEMIC study. Presented at 47th Scientific Session of American College of Cardiology Meeting, Atlanta, GeorgiaGoogle Scholar
  14. 14.
    Havlir DV, Dubé MP, Sattler FR et al (1996) Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 335: 392–398PubMedCrossRefGoogle Scholar
  15. 15.
    Kaski JC, Chester MR, Chen L et al (1995) Rapid angiographic progression of coronary artery disease in patients with angina pectoris. Circulation 92: 2058–2065PubMedGoogle Scholar
  16. 16.
    Gupta S, Camm AJ (1997) Chlamydia pneumoniae and coronary heart disease: coincidence, association or causation? BMJ 314: 1778–1779PubMedCrossRefGoogle Scholar
  17. 17.
    Gupta S, Kaski JC, Camm AJ (1998) Antibiotic therapy in coronary heart disease: hype versus hope. Br J Cardiol 5: 65–66Google Scholar

Copyright information

© Springer-Verlag Italia, Milano 1999

Authors and Affiliations

  • S. Gupta
  • J. C. Kaski

There are no affiliations available

Personalised recommendations